Omeros Corporation
OMER
3,58 €
Share price
8.36%
Change (1 day)
-28.00%
Change (1 year)
Categories
Revenue for Omeros Corporation (OMER)
Revenue in 2025 (TTM): N/A
In 2024 the company made a revenue of N/A a decrease over the revenue in the year 2023 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Omeros Corporation from 2009 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
2025 (TTM)  | N/A | |
| 2024 | N/A | |
| 2023 | N/A | |
| 2022 | N/A | -100% |
| 2021 | -€70.55 Million | -217.55% |
| 2020 | €60.01 M | -39.87% |
| 2019 | €99.8 M | 282.28% |
| 2018 | €26.1 M | -51.68% |
| 2017 | €54.02 M | 36.55% |
| 2016 | €39.56 M | 220.24% |
| 2015 | €12.35 M | 2687.81% |
| 2014 | €0.44 M | -61.75% |
| 2013 | €1.15 M | -74.55% |
| 2012 | €4.55 M | 30.69% |
| 2011 | €3.48 M | 120.13% |
| 2010 | €1.58 M | 57.02% |
| 2009 | €1 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Eterna Therapeutics ERNA | €0.46 M | N/A | 🇺🇸 USA |
 Genetic Technologies GENE | €14.75 M | N/A | 🇦🇺 Australia |
 Pfizer PFE | €53.88 B | N/A | 🇺🇸 USA |
 Johnson & Johnson JNJ | €77.06 B | N/A | 🇺🇸 USA |